Mustang Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

License, Clinical Trial and Sponsored Research Agreements (Tables)

3 Months Ended

Mar. 31, 2019

License Agreement Disclosure [Abstract]

Research and Development Arrangement, Contract to Perform for Others [Table Text Block]

For the three months ended March 31, 2019 and 2018, the Company recorded the following expense in research and development for licenses acquired:

	For the three months ended March 31,
($ in thousands)	2019		2018
City of Hope
CD123	$	250	$	-
Manufacturing		-		75
Nationwide Children's Hospital - C134		200		-
Total	$	450	$	75

For the three months ended March 31, 2019 and 2018, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

	For the three months ended March 31,
	2019		2018
($ in thousands)
City of Hope	$	500	$	500
City of Hope - CD123		303		150
City of Hope - IL13Rα2		342		360
City of Hope - Manufacturing		114		114
Fred Hutch - CD20		267		266
BIDMC - CRISPR		69		-
Total	$	1,595	$	1,390